28
Participants
Start Date
January 7, 2017
Primary Completion Date
August 31, 2021
Study Completion Date
August 31, 2021
Pembrolizumab 200 mg IV single dose
Pembrolizumab 200 mg IV single dose, 21 days later surgery
Pembrolizumab 200 mg IV twice interval 21 days
Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
Pembrolizumab 100 mg I.V single dose
Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
Surgical resection of tumor
Surgical resection of tumor by any of the acceptable procedures
Sheba Medical Center, Ramat Gan
Merck Sharp & Dohme LLC
INDUSTRY
Jair Bar, M.D., Ph.D.
OTHER_GOV